InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.46
(
0.77%
)
Bitcoin
63,836.30
(
0.34%
)
Post# of 13742
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

~MulaGreen~

Send PM Follow Ignore
Followers 1171
Posts 34538
Boards Moderated 0
Alias Born 03/26/2007

~MulaGreen~

Re: ~MulaGreen~ post# 10763

Wednesday, 09/29/2021 8:44:58 AM

Wednesday, September 29, 2021 8:44:58 AM

Post# of 13742

In addition to surpassing the expectations from the MOE, the Company also received interest from the MOE in purchasing Escozine®, Medolife’s lead drug candidate.
The report included clinical observations made by the Company on the potential therapeutic and palliative properties of Escozine® in patients who have tested positive for the SARS-CoV-2 (COVID-19) virus, and preventative properties in hospital staff that reported zero new infections over the course of the clinical observation.
The MOE is interested in purchasing Escozine® as a preventative alternative medicine for its employees.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up